Antimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Biochim Biophys Acta Rev Cancer. 2020 Aug;1874(1):188388. doi: 10.1016/j.bbcan.2020.188388. Epub 2020 Jun 23.
Bacteria have long been known as one of the primary causative agents of cancer, however, recent studies suggest that they can be used as a promising agent in cancer therapy. Because of the limitations that conventional treatment faces due to the specific pathophysiology and the tumor environment, there is a great need for the new anticancer therapeutic agents. Bacteriotherapy utilizes live, attenuated strains or toxins, peptides, bacteriocins of the bacteria in the treatment of cancer. Moreover, they are widely used as a vector for delivering genes, peptides, or drugs to the tumor target. Interestingly, it was found that their combination with the conventional therapeutic approaches may enhance the treatment outcome. In the genome editing era, it is feasible to develop a novel generation of therapeutic bacteria with fewer side effects and more efficacy for cancer therapy. Here we review the current knowledge on the dual role of bacteria in the development of cancer as well as cancer therapy.
细菌一直以来被认为是癌症的主要致病因素之一,然而,最近的研究表明,它们可以被用作癌症治疗中一种有前途的药物。由于传统治疗方法受到特定病理生理学和肿瘤环境的限制,因此非常需要新的抗癌治疗药物。细菌疗法利用活的、减毒的菌株或毒素、细菌肽、细菌素来治疗癌症。此外,它们还被广泛用作将基因、肽或药物递送到肿瘤靶标的载体。有趣的是,人们发现它们与传统治疗方法的结合可以提高治疗效果。在基因组编辑时代,开发新一代具有更少副作用和更高疗效的治疗用细菌来治疗癌症是可行的。在这里,我们综述了细菌在癌症发展和癌症治疗中双重作用的最新知识。